Sun, Jun 21, 2026
Amir Asghary1 
, Marie Saghaeian Jazi2 , Seyed Mostafa Mir3 , Abbas Doulani4 , Hamid Reza Joshaghani5
, Marie Saghaeian Jazi2 , Seyed Mostafa Mir3 , Abbas Doulani4 , Hamid Reza Joshaghani5
1- Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran. Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. 0000-0003-0344-3870
2- Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran
3- Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
4- Department of Information Science, Faculty of Education and Psychology, Alzahra University, Tehran, Iran
5- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran. 0000-0003-3392-304X ,joshaghani@goums.ac.ir
2- Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran
3- Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
4- Department of Information Science, Faculty of Education and Psychology, Alzahra University, Tehran, Iran
5- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran. 0000-0003-3392-304X ,
Abstract: (1003 Views)
Background and Objectives: Gastric cancer (GC), particularly adenocarcinoma, remains a global health burden with high mortality due to late-stage diagnosis and limited reliable biomarkers for disease monitoring. Lipid metabolism plays a crucial role in tumor biology, and serum lipid-related markers, including apolipoproteins, have been suggested as potential non-invasive indicators of tumor progression. This study aimed to evaluate the association between serum lipid profiles and tumor stage and histological grade in patients with gastric adenocarcinoma.
Methods: Fifty patients diagnosed with gastric adenocarcinoma were enrolled. Serum levels of total cholesterol, triglycerides, HDL-C, LDL-C, ApoA1, and ApoB were measured. Patients were categorized into early (stages I–II) and advanced (stages III–IV) tumor stages, as well as into moderately differentiated versus poorly differentiated grades. The Shapiro-Wilk test was used to assess data normality. Parametric and non-parametric tests were applied accordingly. A p-value < 0.05 was considered statistically significant.
Results: ApoB was the only parameter showing a significant association with tumor stage. Patients with advanced-stage GC had significantly lower mean ApoB levels compared to those in early stages (52.4 ± 2.6 vs. 63.4 ± 5.2 mg/dl, p = 0.042). No statistically significant differences were observed in ApoA1, HDL-C, total cholesterol, triglycerides, LDL-C, or VLDL, for either tumor stage or histological grade.
Conclusion: ApoB levels appear to decline with advancing tumor stage in gastric adenocarcinoma, suggesting a potential role as a marker to evaluate disease burden. While no association was found with tumor grade, further validation in larger prospective studies incorporating metabolic and inflammatory covariates is warranted.
Methods: Fifty patients diagnosed with gastric adenocarcinoma were enrolled. Serum levels of total cholesterol, triglycerides, HDL-C, LDL-C, ApoA1, and ApoB were measured. Patients were categorized into early (stages I–II) and advanced (stages III–IV) tumor stages, as well as into moderately differentiated versus poorly differentiated grades. The Shapiro-Wilk test was used to assess data normality. Parametric and non-parametric tests were applied accordingly. A p-value < 0.05 was considered statistically significant.
Results: ApoB was the only parameter showing a significant association with tumor stage. Patients with advanced-stage GC had significantly lower mean ApoB levels compared to those in early stages (52.4 ± 2.6 vs. 63.4 ± 5.2 mg/dl, p = 0.042). No statistically significant differences were observed in ApoA1, HDL-C, total cholesterol, triglycerides, LDL-C, or VLDL, for either tumor stage or histological grade.
Conclusion: ApoB levels appear to decline with advancing tumor stage in gastric adenocarcinoma, suggesting a potential role as a marker to evaluate disease burden. While no association was found with tumor grade, further validation in larger prospective studies incorporating metabolic and inflammatory covariates is warranted.
Keywords: Adenocarcinoma, Stomach, Apolipoprotein B, Lipid Metabolism, Neoplasm Staging, Neoplasm Grading
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J. 2022;44(16):1394-407. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Shen JG, Jin LD, Dong MJ, Wang LB, Zhao WH, Shen J. Low level of serum high-density lipoprotein cholesterol in gastric cancer correlates with cancer progression but not survival. Transl Cancer Res. 2020;9(10):6206-13. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Pih GY, Gong EJ, Choi JY, Kim M-J, Ahn JY, Choe J, et al. Associations of serum lipid level with gastric cancer risk, pathology, and prognosis. Cancer Res Treat. 2021;53(2):445-56. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Peng Q, Zhan C, Shen Y, Xu Y, Ren B, Feng Z, et al. Blood lipid metabolic biomarkers are emerging as significant prognostic indicators for survival in cancer patients. BMC Cancer. 2024;24(1):1549. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Xu S, Fan Y, Tan Y, Zhang L, Li X. Association between blood lipid levels and risk of gastric cancer: A systematic review and meta-analysis. PLoS One. 2023;18(7):e0288111. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Li F, Han M, Gao X, Du X, Jiang C. APOA1 mRNA and serum APOA1 protein as diagnostic and prognostic biomarkers in gastric cancer. Transl Cancer Res. 2024;13(5):2141. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Ma M-z, Yuan S-q, Chen Y-m, Zhou Z-w. Preoperative apolipoprotein B/apolipoprotein A1 ratio: a novel prognostic factor for gastric cancer. Onco Targets Ther. 2018:11:2169-76. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Zhang H, Liu Y, Feng L, Wang L, Han J, Zhang X, et al. Blood lipid profiles associated with metastatic sites in advanced gastric cancer.BMC Gastroenterol. 2024;24(1):391. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Zhang D, Hu R-h, Cui X-m, Jiang X-h, Zhang S. Lipid levels and insulin resistance markers in gastric cancer patients: diagnostic and prognostic significance. BMC Gastroenterol. 2024;24(1):373. [View at Publisher] [DOI]
12. Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Triglyceride-glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study. BMC Endocr Disord. 2020;20(1):113. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Li F, Dou J, Wei L, Li S, Liu J. Biomarkers of lipid metabolism in gastric cancer: a case control study. BMC Cancer. 2024;24(1):455. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Pagliari F, Di Franco S, Tirinato L. Lipid alterations in cancer development, resistance and recurrence. Front Cell Dev Biol. 2024;12:1493626. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Chen Y, Zhang J, Zhang Y, Zhu L. Effect of statin use on risk and mortality of gastric cancer: a meta-analysis. Anticancer Drugs. 2023;34(8):901-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Yu Y, Zheng Z, Gao X, Gu Y, Zhang M, Hu B, et al. Plasma metabolomic signatures of H. pylori infection, alcohol drinking, smoking, and risk of gastric cancer. Mol Carcinog. 2025;64(3):463-74. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Dai J, Li Q, Quan J, Webb G, Liu J, Gao K. Construction of a lipid metabolism-related and immune-associated prognostic score for gastric cancer. BMC Med Genomics. 2023;16(1):93. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Contact us
Tel & Fax: (+98) 17-32450093
E-mail:
goums.ac.ir
yahoo.com